Sulforaphane Inhibits Osteoclastogenesis by Inhibiting Nuclear Factor-κB

  • Kim, Soo-Jin (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Kang, So-Young (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Shin, Hyun-Hee (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Choi, Hye-Seon (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan)
  • Received : 2005.07.05
  • Accepted : 2005.08.26
  • Published : 2005.12.31

Abstract

We show that sulforaphane inhibits osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-${\kappa}B$ ligand (RANKL) in osteoclast (OC) precursors. Sulforaphane, an aliphatic isothiocyanate, is a known cancer chemo-preventative agent with anti-oxidative properties. Nuclear factor-${\kappa}B$ (NF-${\kappa}B$) is a critical transcription factor in RANKL-induced osteoclastogenesis, and electrophoretic mobility shift assays (EMSAs) and assay of NF-${\kappa}B$-mediated secreted alkaline phosphatase (SEAP) revealed that sulforaphane selectively inhibited NF-${\kappa}B$ activation induced by RANKL. Inhibition may involve interaction of sulforaphane with thiol groups, since it was prevented by reducing agents.

Keywords

Bone Marrow-derived Macrophages;NF-${\kappa}B$;Osteoclastogenesis;RANKL;Sulforaphane;Thiol

Acknowledgement

Supported by : KOSEF

References

  1. Arai, F., Miyamoto, T., Ohnetda, O., Inada, T., Sudo, T., et al. (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor ${\kappa}B$ (RANK) receptor. J. Exp. Med. 190, 1741-1746 https://doi.org/10.1084/jem.190.12.1741
  2. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., et al. (1997) Requirement for NF-${\kappa}B$ in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 https://doi.org/10.1101/gad.11.24.3482
  3. Rassi, C. M., Lieberherr, M., Chaumaz, G., Pointillart, A., and Cournot, G. (2002) Down-regulation of osteoclast differentiation by daidzein via caspase 3. J. Bone Miner. Res. 17, 630-638 https://doi.org/10.1359/jbmr.2002.17.4.630
  4. Roodman, G. D. (1996) Advances in bone biology: the osteoclast. Endocr. Rev. 17, 308-332
  5. Schreck, R., Meier, B., Mannel, D. N., Droge, W., and Baeuerle, P. A. (1992) Dithiocarbamates as potent inhibitors of nuclear factor ${\kappa}B$ activation in intact cells. J. Exp. Med. 175, 1181-1194 https://doi.org/10.1084/jem.175.5.1181
  6. Shevdo, N. K., Bendixen, A. C., Dienger, K. M., and Pike, J. W. (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97, 7829-7834
  7. Yamagashi, T., Otsuka, E., and Hagawara, H. (2001) Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomease II in osteoclastogenesis. Endocrinology 142, 3632-3637 https://doi.org/10.1210/en.142.8.3632
  8. Zhang, Y. (2000) Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 21, 1175-1182 https://doi.org/10.1093/carcin/21.6.1175
  9. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., et al. (1997) Osteopetrosis in mice lacking NF-${\kappa}B1$ and NF-${\kappa}B2$. Nat. Med. 3, 1285-1289 https://doi.org/10.1038/nm1197-1285
  10. Morabito, N., Crisafulli, A., Vergara, C., Gaudio, A., Lasco, A., et al. (2002) Effects of genistein and hormone replacement therapy on bone loss in early postmenopausal woman: a randomized double-blind placebo-controlled study. J. Bone Miner. Res. 17, 1904-1912 https://doi.org/10.1359/jbmr.2002.17.10.1904
  11. Jimi, E., Nakamura, I., Amano, H., Taguchi, Y., Tsurukai, T., et al. (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137, 2187-2190 https://doi.org/10.1210/en.137.5.2187
  12. Zhang, Y., Talalay, P., Cho, C. G., and Posner, G. H. (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA 89, 2399-2403
  13. Schmidt, T. J., Lyb, G., Pajl, H. L., and Merfor, I. (1999) Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions. Bioorg. Med. Chem. 7, 2849-2855 https://doi.org/10.1016/S0968-0896(99)00234-5
  14. Nakagawa, H., Wachi, M., Woo, J. T., Kato, M., Kasai, S., et al. (2002) Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem. Biophys. Res. Commun. 292, 94-101 https://doi.org/10.1006/bbrc.2002.6622
  15. Baldwin, A. S. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann. Rev. Immunol. 14, 649-683 https://doi.org/10.1146/annurev.immunol.14.1.649
  16. Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., et al. (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA 99, 7610-7615
  17. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 https://doi.org/10.1210/er.20.3.345
  18. Hiramoto, M., Shimizu, N., Sugimoto, K., Tang, J., Kawakami, Y., et al. (1998) Nuclear targeted suppression of NF-${\kappa}B$ activity by the novel quinone derivative E3330. J. Immunol. 160, 810-819
  19. Hecht, S. S. (1999) Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J. Nutr. 129, 768S-774S
  20. Tsai, S. H., Lin-Shiau, S. Y., and Lin, J. K. (1999) Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126, 673-680 https://doi.org/10.1038/sj.bjp.0702357
  21. Gerhauser, C., You, M., Liu, J., Moriarty, R. M., Hawthorne, M., et al. (1997) Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drugmetabolizing enzymes. Cancer Res. 57, 272-278
  22. Yao, K. S., Hageboutros, A., Ford, P., and O-Dwyer, P. J. (1997) Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol. Pharmcol. 51, 422-430
  23. Lee, Z. H. and Kim, H. H. (2003) Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214 https://doi.org/10.1016/S0006-291X(03)00695-8
  24. Wang, B. and Williamson, G. (1996) Transcriptional regulation of the human NAD(P)H:quinone oxidoreductase (NQO1) gene by monofunctional inducers. Biochim. Biophys. Acta 1307, 104-110 https://doi.org/10.1016/0167-4781(96)00028-0
  25. Sen, C. K. (2000) Cellular thiols and redox-regulated signal transduction. Curr. Top Cell Regul. 36, 1-30 https://doi.org/10.1016/S0070-2137(01)80001-7
  26. Zhang, Y., Kensler, T. W., Cho, C. G., Posner, G. H., and Talalay, P. (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. USA 91, 3147-3150
  27. Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., and Gerhauser, C. (2001) Nuclear factor-${\kappa}B$ is a molecular target for sulforaphane- mediated anti-inflammatory mechanism. J. Biol. Chem. 276, 32008-32015 https://doi.org/10.1074/jbc.M104794200
  28. New, S. A., Robins, S. P., Campbell, M. K., Martin, J. C., Garton, M. J., et al. (2000) Dietary influences on bone mass and bone metabolism: further evidences on a positive link between fruit and vegetable consumption and bone health? Am. J. Clin. Nutr. 71, 142-151
  29. Umezawa, K. and Chaicharoenpong, C. (2002) Molechlar design and biological activities of NF-kappa B inhibitors. Mol. Cells 14, 163-167
  30. Wattel, A., Kamel, S., Prouillet, C., Petit, J. P., lorget, F., et al. (2004) Flavonoid quercetin decreasesosteoclastic differentiation induced by RANKL via a mechanism involving NF-${\kappa}B$ and AP-1. J. Cell Biochem. 92, 285-295 https://doi.org/10.1002/jcb.20071
  31. Gao, X., Dinkova-Kostova, A. T., and Talalay, P. (2001) Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA 98, 15221-15226